Vacuolar Hepatopathy

Vacuolar hepatopathy (VH) is a histopathological pattern in the liver characterized by the presence of hepatocytes containing intracytoplasmic vacuoles, which may be empty (lipid) or contain glycogen. This condition is most commonly recognized in dogs, particularly in association with hypercortisolism (Cushing's syndrome), but can also occur secondary to various metabolic, toxic, or idiopathic causes. The vacuoles are typically clear on hematoxylin and eosin (H&E) staining, and special stains (e.g., Periodic acid-Schiff for glycogen, Oil Red O for lipid) can differentiate the content. VH is often an incidental finding on liver biopsy, but it can be associated with elevated liver enzymes, hepatomegaly, and, in severe cases, progressive hepatic dysfunction. The clinical significance ranges from benign to potentially contributing to chronic hepatitis or cirrhosis if the underlying cause is not addressed.

The primary etiology of vacuolar hepatopathy in dogs is excessive endogenous or exogenous glucocorticoids. Endogenous hypercortisolism (pituitary-dependent or adrenal-dependent Cushing's syndrome) is the most common cause. Exogenous glucocorticoid administration (e.g., prednisone, dexamethasone) for various inflammatory or immune-mediated conditions can also induce VH. Other potential causes include: chronic stress or illness leading to cortisol elevation; diabetes mellitus (due to glycogen accumulation); hyperlipidemia; hypothyroidism (less commonly); exposure to certain toxins (e.g., aflatoxin, some plants); and idiopathic vacuolar hepatopathy of unknown cause. In cats, vacuolar hepatopathy is less common but can occur with diabetes mellitus or hyperthyroidism. Rarely, it may be associated with portosystemic shunts or other metabolic disorders.

Vacuolar hepatopathy is most frequently diagnosed in dogs, with a higher prevalence in middle-aged to older animals (typically >6 years). There is no strong breed predilection, but breeds predisposed to hypercortisolism, such as Poodles, Dachshunds, Boxers, and Boston Terriers, may be overrepresented. Both sexes are affected, though some studies suggest a slight female predominance for pituitary-dependent hypercortisolism. The condition is less common in cats, but when present, it is often associated with diabetes mellitus or hyperthyroidism. Geographic distribution is not specific, but the incidence may reflect the prevalence of underlying endocrine disorders in the population.

The pathophysiology of vacuolar hepatopathy is primarily driven by glucocorticoid excess. Glucocorticoids stimulate glycogen synthesis and accumulation in hepatocytes, leading to glycogen-type vacuoles. They also promote lipolysis and fatty acid uptake, contributing to lipid-type vacuoles. The vacuoles cause hepatocyte swelling, which can lead to compression of adjacent sinusoids and bile canaliculi, resulting in cholestasis and elevated liver enzymes (particularly alkaline phosphatase, ALP). In dogs, glucocorticoids induce a specific isoform of ALP (corticosteroid-induced ALP), which is a sensitive marker for VH. Chronic glucocorticoid excess can also impair hepatic regeneration and immune function, potentially predisposing to secondary infections or progression to chronic hepatitis. In cases of diabetes mellitus, insulin deficiency or resistance leads to increased glycogenolysis and gluconeogenesis, but also glycogen accumulation in the liver due to impaired utilization. The exact mechanisms of idiopathic VH are unclear but may involve subclinical cortisol dysregulation or other metabolic factors.

Predisposing factors include: endogenous hypercortisolism (pituitary or adrenal tumors); iatrogenic glucocorticoid therapy (especially long-term or high-dose); poorly controlled diabetes mellitus; hyperlipidemia; obesity; chronic inflammatory or neoplastic disease causing stress-induced cortisol elevation; and possibly breed-related genetic susceptibility to glucocorticoid sensitivity. Age is a risk factor, as endocrine disorders are more common in older animals. Concurrent medications that affect hepatic metabolism (e.g., phenobarbital) may also contribute. In cats, hyperthyroidism and diabetes mellitus are the main predisposing conditions.

Clinical signs are often subtle and may be absent, especially in early or mild cases. When present, they are typically related to the underlying cause (e.g., hypercortisolism) or to hepatic dysfunction. Common signs include: polyuria, polydipsia, polyphagia (if hypercortisolism); abdominal distension (hepatomegaly); lethargy; weight loss or gain; poor hair coat; and occasionally jaundice if cholestasis is severe. In advanced cases, signs of hepatic failure such as hepatic encephalopathy, ascites, or bleeding tendencies may occur. Physical examination may reveal hepatomegaly, pot-bellied appearance, and signs of endocrine disease (e.g., alopecia, calcinosis cutis).

Differential diagnoses for vacuolar hepatopathy include: 1) Chronic hepatitis (lymphocytic or plasmacytic inflammation) – distinguished by histopathology showing inflammatory infiltrate and hepatocellular necrosis; 2) Hepatic lipidosis (especially in cats) – characterized by marked lipid vacuolation and often associated with anorexia; 3) Glycogen storage disease (rare, congenital) – presents in young animals with hypoglycemia and hepatomegaly; 4) Hepatic neoplasia (e.g., hepatocellular adenoma/carcinoma) – identified by imaging and histopathology; 5) Cholangiohepatitis – inflammatory disease of bile ducts and liver, often with fever and abdominal pain; 6) Amyloidosis – deposition of amyloid in liver, confirmed by Congo red staining; 7) Toxic hepatopathy (e.g., aflatoxin, xylitol) – history of exposure and acute onset; 8) Portosystemic shunt – microhepatica, high bile acids, and histopathology showing atrophy; 9) Diabetes mellitus – hyperglycemia and glycosuria; 10) Hyperthyroidism in cats – elevated T4 and clinical signs. Definitive diagnosis relies on liver biopsy and histopathology.

The diagnostic approach begins with a thorough history and physical examination, focusing on signs of endocrine disease. Initial laboratory tests include a complete blood count (CBC), serum biochemistry profile, and urinalysis. Key findings include elevated ALP (often markedly), with normal or mildly elevated ALT, and possibly elevated gamma-glutamyltransferase (GGT). If hypercortisolism is suspected, perform an ACTH stimulation test or low-dose dexamethasone suppression test. Abdominal ultrasound is recommended to assess liver size and echogenicity and to evaluate adrenal glands for tumors. If vacuolar hepatopathy is suspected based on imaging and endocrine testing, a liver biopsy (ultrasound-guided or surgical) is the gold standard for diagnosis. Histopathology reveals vacuolated hepatocytes, and special stains (PAS, Oil Red O) can differentiate glycogen from lipid. In cases where the underlying cause is unclear, further testing for diabetes mellitus (glucose, fructosamine), thyroid function, and other metabolic disorders may be warranted.

Hematology: Often unremarkable, but may show a stress leukogram (neutrophilia, lymphopenia, eosinopenia) in hypercortisolism. Serum Biochemistry: Marked elevation of ALP (often 2-5 times normal or higher) is the hallmark; ALT may be normal or mildly elevated; GGT may be elevated; total bilirubin may be normal or mildly increased; cholesterol and triglycerides may be elevated; glucose may be elevated if diabetes mellitus is present; albumin and total protein may be normal or decreased in chronic liver disease; bile acids may be elevated if hepatic function is compromised. Urinalysis: May show low urine specific gravity (if hypercortisolism), glucosuria (if diabetes), or proteinuria (if concurrent glomerular disease). Blood Gas Analysis: Usually normal unless severe hepatic failure. Specific Biomarkers: Corticosteroid-induced ALP isoenzyme can be measured; ACTH stimulation test or low-dose dexamethasone suppression test for hypercortisolism; fructosamine for diabetes; thyroid panel if hypothyroidism suspected. Serology/PCR: Not typically needed unless infectious causes are considered.

Radiography: Abdominal radiographs may show hepatomegaly (enlarged liver silhouette). Thoracic radiographs may be indicated if metastatic disease is suspected. Ultrasonography: Liver may be diffusely hyperechoic (increased echogenicity) due to vacuolation, with normal or slightly increased size. Adrenal glands may be enlarged or asymmetric if hypercortisolism is present. Doppler ultrasound can assess hepatic vasculature. Computed Tomography (CT): CT can provide detailed assessment of liver size, parenchymal changes, and adrenal glands; useful for surgical planning if adrenal tumor is suspected. Magnetic Resonance Imaging (MRI): MRI is rarely used for liver evaluation but may be helpful for pituitary imaging in pituitary-dependent hypercortisolism. Endoscopy: Not directly useful for liver, but can be used to obtain biopsies via endoscopic ultrasound if available. Fluoroscopy: Not typically used.

Fine Needle Aspiration (FNA): Cytology of liver aspirates may show hepatocytes with clear vacuoles, but FNA is not reliable for distinguishing vacuolar hepatopathy from other conditions and may miss inflammation or fibrosis. Histopathology: On biopsy, hepatocytes are swollen with intracytoplasmic vacuoles. Special stains: Periodic acid-Schiff (PAS) stains glycogen (pink), and Oil Red O stains lipid (red) on frozen sections. The vacuoles may be diffuse or periportal. There is typically no significant inflammation or necrosis, but chronic cases may show mild fibrosis. In severe cases, there may be cholestasis (bile pigment in canaliculi). Histopathology is essential to rule out other diseases like hepatitis or neoplasia.

Treatment of vacuolar hepatopathy is primarily directed at the underlying cause. If iatrogenic glucocorticoid therapy is the cause, gradual tapering and discontinuation of the drug is recommended. For hypercortisolism, medical management with trilostane (Vetoryl) or mitotane (Lysodren) is indicated. Trilostane dose: 1-3 mg/kg PO q12h initially, adjust based on ACTH stimulation test. Mitotane: for pituitary-dependent hypercortisolism, loading dose 50 mg/kg/day PO divided for 7-10 days, then maintenance 50 mg/kg/week. For adrenal tumors, surgical adrenalectomy may be considered. If diabetes mellitus is present, insulin therapy (e.g., NPH insulin 0.5-1.0 U/kg SC q12h) is required. Supportive care includes a high-quality, easily digestible diet; for hepatic support, antioxidants such as S-adenosylmethionine (SAMe) 20 mg/kg PO q24h, and vitamin E 10-20 IU/kg PO q24h may be used. Ursodeoxycholic acid (UDCA) 10-15 mg/kg PO q24h can be given for cholestasis. In cases of hepatic failure, additional management includes fluid therapy, lactulose for encephalopathy, and nutritional support. Surgery is rarely needed for the liver itself.

The prognosis for vacuolar hepatopathy is generally good if the underlying cause is identified and treated. In cases of iatrogenic glucocorticoid administration, resolution of vacuolation occurs after drug withdrawal. For hypercortisolism, successful management with trilostane or mitotane can lead to improvement in liver enzymes and clinical signs. However, if the condition progresses to chronic hepatitis or cirrhosis, the prognosis is guarded. The presence of marked fibrosis or cirrhosis on biopsy indicates a poorer prognosis. Overall, with appropriate treatment, many dogs live for years with good quality of life. In cats, the prognosis depends on the underlying disease (e.g., diabetes mellitus) and response to treatment.

Follow-up is essential to monitor response to treatment and adjust medications. For hypercortisolism, recheck ACTH stimulation tests at 10-14 days after starting trilostane, then every 3-6 months. Monitor clinical signs and liver enzymes (ALP, ALT) every 1-3 months initially, then every 6 months. For diabetes mellitus, monitor glucose curves and fructosamine every 2-3 months. Repeat liver biopsy is not typically needed unless there is clinical deterioration. If the patient is on long-term glucocorticoids, taper slowly and monitor for signs of hypoadrenocorticism. Regular physical examinations and blood work are recommended every 6-12 months for lifelong management.

Pearls: 1) Marked ALP elevation with normal or mild ALT elevation is a classic clue for vacuolar hepatopathy; 2) Always consider hypercortisolism in any dog with unexplained ALP elevation; 3) Liver biopsy is the gold standard for diagnosis, but FNA is not reliable; 4) Special stains (PAS, Oil Red O) can differentiate glycogen from lipid vacuoles; 5) Treatment of the underlying cause often resolves the vacuolar changes. Pitfalls: 1) Do not assume vacuolar hepatopathy is benign; it can progress to fibrosis; 2) Avoid unnecessary liver biopsies if endocrine disease is confirmed and liver enzymes are only mildly elevated; 3) Do not use corticosteroids to treat vacuolar hepatopathy; 4) Be cautious with trilostane dosing, as overdose can cause hypoadrenocorticism; 5) In cats, vacuolar hepatopathy may be mistaken for hepatic lipidosis; differentiate by history and histopathology.

For hypercortisolism: Trilostane (Vetoryl) – initial dose 1-3 mg/kg PO q12h, adjust based on ACTH stimulation test (target post-pill cortisol 1.5-5.5 μg/dL). Mitotane (Lysodren) – for pituitary-dependent hypercortisolism: loading dose 50 mg/kg/day PO divided for 7-10 days, then maintenance 50 mg/kg/week; for adrenal tumors: 50-75 mg/kg/day PO divided until cortisol <2 μg/dL, then maintenance. For diabetes mellitus: NPH insulin (Humulin N) – initial dose 0.5-1.0 U/kg SC q12h, adjust based on glucose curves. For hepatic support: S-adenosylmethionine (SAMe) – 20 mg/kg PO q24h; Vitamin E – 10-20 IU/kg PO q24h; Ursodeoxycholic acid (UDCA) – 10-15 mg/kg PO q24h. For iatrogenic glucocorticoid withdrawal: taper prednisone by 20-25% every 2-4 weeks. Always monitor for adverse effects and adjust doses based on clinical response and laboratory values. Contraindications: Trilostane should not be used in animals with primary hepatic disease or renal insufficiency; mitotane is contraindicated in animals with severe hepatic dysfunction. Drug interactions: Trilostane may interact with ACE inhibitors and potassium-sparing diuretics; mitotane may increase the metabolism of other drugs.

Several studies have characterized vacuolar hepatopathy in dogs. A landmark study by Gieger et al. (2003) described the association between vacuolar hepatopathy and hypercortisolism, noting that ALP elevation is a sensitive marker. Another study by Fracassi et al. (2015) evaluated the diagnostic value of liver biopsy in dogs with suspected hypercortisolism and found that vacuolar hepatopathy was the most common histopathological finding. ACVIM consensus guidelines on the diagnosis and treatment of hypercortisolism (Behrend et al., 2013) recommend trilostane as the first-line medical therapy. Regarding treatment, a study by Braddock et al. (2003) showed that trilostane effectively controlled clinical signs and reduced ALP levels in dogs with pituitary-dependent hypercortisolism. For hepatic support, a randomized controlled trial by Webster et al. (2019) demonstrated that SAMe and vitamin E improved liver enzyme levels in dogs with chronic hepatitis, which may be beneficial in vacuolar hepatopathy. Overall, the evidence supports that addressing the underlying endocrine disorder is crucial for resolution of vacuolar hepatopathy.